DWDepei Wu

Depei Wu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Depei Wu has a total of 420 co-authors. Here are the top co-authors by number of shared publications:

  • Aining Sun

    National Clinical Research Center for Hematologic Disease The First Affiliated Hospital of Soochow University Suzhou China

    16 shared publications
  • Xiao Ma

    The First Affiliated Hospital of Soochow University, Suzhou, China

    14 shared publications
  • Yang Xu

    National Clinical Research Center for Hematologic Disease The First Affiliated Hospital of Soochow University Suzhou China

    12 shared publications
  • Xiaojin Wu

    The First Affiliated Hospital of Soochow University, Suzhou, China

    11 shared publications
  • Xiaowen Tang

    The First Affiliated Hospital of Soochow University, Suzhou, China

    11 shared publications
  • Huiying Qiu

    National Clinical Research Center for Hematologic Disease The First Affiliated Hospital of Soochow University Suzhou China

    10 shared publications

Latest Publications

  • Open Access

    Efficacy and toxicity of SEAM (semustine, etoposide, cytarabine, and melphalan) conditioning regimen followed by autologous stem cell transplantation in lymphoma

    by Lihong Zhang, Haifei Yang, Chongsheng Qian, Jihao Zhou, Qian Zhu, Yibin Jiang, Shuo Liu, Xiaochen Chen, Ting Xu, Changju Qu, et al.

    The aim of this retrospective study was to evaluate the safety and efficacy of SEAM regimen followed by auto-SCT in lymphoma.We retrospectively reviewed the records of patients with lymphoma who un...


  • Impact of disease status at allogeneic stem cell transplantation on adolescent and young adult patients with early T‐cell precursor acute lymphoblastic leukemia

    by Tongyan Meng, Jiaqian Qi, Yuanxin Zhu, Yang Xu, Feng Chen, Shengli Xue, Miao Miao, Suning Chen, Yue Han, Xiaowen Tang, et al.

    Early T‐cell precursor (ETP) acute lymphoblastic leukemia (ALL) is an aggressive subset of T‐cell ALL and the role of allogeneic hematopoietic stem cell transplantation (allo‐HSCT) in adolescent and young adult (AYA) patients has not been sufficiently described. We retrospectively analyzed the data of 30 AYA patients (19 in first complete remission [CR1], 3 in CR2 and 8 with active disease) with ETP‐ALL who underwent myeloablative allo‐HSCT from HLA‐matched related, n=2, unrelated, n=5, or HLA‐haploidentical related, n=23 donors with an emphasis on the impact of disease status on the outcomes of transplant. The stem cell source was unmanipulated G‐CSF mobilized bone marrow or peripheral blood stem cells. All patients achieved neutrophil engraftment with full donor chimerism. The cumulative incidences of grade II to IV acute graft‐versus‐host disease (GVHD) and chronic GVHD at 2 years were 37% and 33%, respectively. Overall, 16 patients died. The causes of death were relapse (8 patients), infection (4 patients) and GVHD (4 patients). The estimated 2‐year overall survival (OS) and leukemia‐free survival (LFS) for the whole cohort were 47.8% and 46.2%, respectively. Patients transplanted in CR1/2 had significantly better 2‐year OS and LFS than patients with active disease (61.7% vs 12.5%, p = 0.02; and 58.3% vs 12.5%, p = 0.04, respectively). There was a trend toward an inferior OS rate in those patients in CR1 with chemoresistance or in CR2 compared with patients in CR1 with chemosensitivity, although this did not reach statistical significance. Our data support allo‐HSCT, especially from HLA‐haploidentical donors as an effective therapeutic strategy in AYA patients with ETP‐ALL and disease status was significantly associated with survival in these patients.


  • Open Access

    IL-Y Aggravates Murine Chronic Graft-Versus-Host Disease by Enhancing T and B Cell Responses

    by Li Wan, Ziqi Jin, Bo Hu, Kangkang Lv, Lei Lei, Yonghao Liu, Yuan Song, Ying Zhu, Huanle Gong, Mimi Xu, et al.

    IL-Y, a synthetic member of IL-12 cytokine family, was found to exert potent immunosuppressive effects by inhibiting the differentiation and activation of Th1 and Th17 cells. However, the role of IL-Y in the development of chronic graft-versus-host disease (cGVHD) remains unknown. Here, using murine models of scleroderma-like and lupus-like cGVHD, we examined the function of IL-Y in the pathogenesis of cGVHD by hydrodynamically injecting minicircle-IL-Y expressing plasmids (MC IL-Y). In contrast with the reported immune suppressive function of IL-Y, administration of MC IL-Y enhanced cGVHD severity reflected by deteriorated multi-organ pathologic damages. In lupus-like cGVHD model, urine protein and the serum anti-dsDNA antibody (IgG) were significantly upregulated by IL-Y treatment. Further study demonstrated that IL-Y impacts both donor T and B cell response. In T cells, IL-Y inhibited the generation of CD4+Foxp3+ regulator T (Treg) cells during the development of cGVHD. IL-Y may also increase the infiltration of pathogenic TNF-α producing CD4+ and CD8+ T cells through IL-27Rα in recipient spleens, as this effect was diminished in IL-27Rα deficient T cells. Moreover, IL-Y enhanced the differentiation of ICOS+ T follicular helper (Tfh) cells. In B cells, the percentage of germinal center (GC) B cells in recipient spleens was significantly upregulated by MC IL-Y plasmid administration. The levels of co-stimulatory molecules, MHC-II and CD86, on B cells were also enhanced by IL-Y expression. Taken together, our data indicated that IL-Y promoted the process of cGVHD by activating pathogenic T and B cells.


  • Immune Thrombocytopenia Plasma-Derived Exosomes Impaired Megakaryocyte and Platelet Production through an Apoptosis Pathway

    by Wenjing Miao, Baoquan Song, Bingyu Shi, Qi Wan, Quansheng Lv, Hanqing Chen, Mingqing Zhu, Leisheng Zhang, Yue Han, Depei Wu

    Reduced megakaryocyte (MK) apoptosis and insufficient platelet production play important roles in the pathogenesis of immune thrombocytopenia (ITP). The contribution of plasma-derived exosomes to the decreased platelet count in ITP has not been entirely understood. Here, we found the percentage of apoptotic MKs in patients with ITP was significantly lower than those in healthy volunteers. In the presence of ITP plasma-derived exosomes (ITP-Exo), the apoptosis of MKs was reduced during the process of MK differentiation in vitro, which contributed to the reduced platelet production by Bcl-xL/caspase signaling. Furthermore, in vivo study demonstrated that ITP-Exo administration led to significantly delayed platelet recovery in mice after 3.5 Gy of irradiation. All these findings indicated that ITP-Exo, as a regulator of platelet production, impaired MK apoptosis and platelet production through Bcl-xL/caspase signaling, unveiling new mechanisms for reduced platelet count in ITP. ∗ W.M. and B.S. contributed equally to this study. Received: 18 August 2019 Accepted: 15 September 2020 Article published online: 29 October 2020 © 2020. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany


  • Tumor Vasculatures: A New Target for Cancer Immunotherapy

    by Zhigang Liu, Yifan Wang, Yuhui Huang, Betty Y.S. Kim, Hong Shan, Depei Wu, Wen Jiang


  • Pretransplant FLT3-ITD levels predict outcome after allogeneic hematopoietic cell transplantation for AML patients in the first remission

    by Li Wan, Mingzhu Xu, Jia Chen, Zuyi Yang, Mimi Xu, Hongjie Shen, Xiaojin Wu, Shengli Xue, Xiao Ma, Yue Han, et al.


  • Modified BuCy is an alternative conditioning regimen for lymphoma patients undergoing autologous stem cell transplantation

    by Haiwen Huang, Lihong Zhang, Yibin Jiang, Shuo Liu, Zhengming Jin, Jia Chen, Xiaofang Xiao, Jia Ruan, Xinyou Zhang, Depei Wu

    The aim of this study is to determine whether the modified BuCy (semustine, cytarabine, busulfan, and cyclophosphamide, mBuCy) conditioning regimen can be safely used as an alternative to the SEAM (semustine, etoposide, cytarabine, and melphalan) regimen by comparing the efficacy and toxicity of the mBuCy and SEAM regimens. We matched 34 pairs of patients with regard to disease status at the time of autologous stem cell transplantation (auto-SCT). We found no significant difference in the time of platelet engraftment between the two groups. Furthermore, neutrophil engraftment was somewhat faster in the mBuCy group than in the SEAM group (median: 9 days vs 10 days, p = 0.015). With regard to toxicity, the incidence of nausea/vomiting, hepatic impairment, renal impairment, pulmonary infection, and treatment-related mortality (TRM) was similar between the two groups. In addition, compared to patients conditioned with SEAM, patients conditioned with mBuCy were less likely to develop mucositis and diarrhea (p = 0.027; p = 0.050). The 2-year progression-free survival (PFS) rates in the mBuCy and SEAM groups were 79% and 70% (p = 0.378), respectively, and the 2-year overall survival (OS) rates were 81% and 78.0%, respectively (p = 0.789). These analyses showed that the mBuCy conditioning regimen was well tolerated and can be used as an alternative to the SEAM regimen for lymphoma.


  • Prognostic value and clinical feature of SF3B1 mutations in myelodysplastic syndromes: A meta-analysis

    by Yaqiong Tang, Miao Miao, Shiyu Han, Jiaqian Qi, Hong Wang, Changgeng Ruan, Depei Wu, Yue Han


  • Open Access

    IL-17C Mitigates Murine Acute Graft-vs.-Host Disease by Promoting Intestinal Barrier Functions and Treg Differentiation

    by Huanle Gong, Shoubao Ma, Shuangzhu Liu, Yonghao Liu, Ziqi Jin, Ying Zhu, Yuan Song, Lei Lei, Bo Hu, Yu Mei, et al.

    Acute graft-vs.-host disease (aGVHD) is one of the major complications and results in high mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). IL-17C is involved in many inflammatory immune disorders. However, the role of IL-17C in aGVHD remains unknown. Here we demonstrated that IL-17C deficiency in the graft significantly promoted alloreactive T cell responses and induced aggravated aGVHD compared with wildtype donors in a fully MHC-mismatched allo-HSCT model. In contrast, IL-17C overexpression ameliorated aGVHD. IL-17C deficiency increased intestinal epithelial permeability and elevated inflammatory cytokine production, leading to an enhanced aGVHD progression. Tregs was reduced in recipients of IL-17C−/− graft, whilst restored after IL-17C overexpression. Decreased Treg differentiation was abrogated after neutralizing IFN-γ, but not IL-6. Moreover, depletion of Tregs diminished the protective effect of IL-17C. Of note, patients with low IL-17C expression displayed higher aGVHD incidence together with poor overall survival, thereby IL-17C could be an independent risk factor for aGVHD development. Our results are the first demonstrating the protective role of IL-17C in aGVHD by promoting intestinal barrier functions and Treg differentiation in a MHC fully mismatched murine aGVHD model. IL-17C may serve as a novel biomarker and potential therapeutic target for aGVHD.


  • Open Access

    Prognostic Significance of Platelet Recovery in Myelodysplastic Syndromes With Severe Thrombocytopenia

    by Yaqiong Tang, Xinyou Zhang, Shiyu Han, Tiantian Chu, Jiaqian Qi, Hong Wang, Xiaowen Tang, Huiying Qiu, Chengcheng Fu, Changgeng Ruan, et al.

    Severe thrombocytopenia is a serious condition that frequently arises in patients with myelodysplastic syndrome (MDS) and is associated with poor prognosis. Few studies have investigated the prognostic significance of platelet recovery in patients with MDS having thrombocytopenia. We retrospectively analyzed 117 patients with de novo MDS complicated with thrombocytopenia (platelet count [PLT] < 100 × 109/L). Patients received decitabine treatment (schedule A) or decitabine followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT; schedule B). Severe thrombocytopenia (PLT < 20 × 109/L), identified in 31 (26.5%) patients, was associated with poor survival. The PLT increased significantly after decitabine treatment in the 2 groups. Patients with thrombocytopenia treated with schedule B showed a superior prognosis compared to those treated with schedule A. On analysis of overall survival by platelet response in patients with severe thrombocytopenia, a significant survival advantage was observed in patients who achieved a platelet response, who would further benefit from allo-HSCT following decitabine therapy. The results indicate a potentially favorable prognostic impact of platelet response achieved with decitabine. Patients with MDS having severe thrombocytopenia may benefit from the effective recovery of platelets and further allo-HSCT following decitabine therapy.